Article Per Year (5 Year)
p-Index From 2021 - 2026
0.888
P-Index
This Author published in this journals
All Journal Journal of Biomedicine and Translational Research Mutiara Medika: Jurnal Kedokteran dan Kesehatan Medica Hospitalia Diponegoro International Medical Journal (DIMJ)
M. Besari Adi Pramono, M. Besari Adi
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
The Level of Depression in Third Trimester Pregnancy, With and Without Anemia Primada, Lyla Fitrania; Wardani, Natalia Dewi; Pramono, M. Besari Adi
Mutiara Medika: Jurnal Kedokteran dan Kesehatan Vol 24, No 1 (2024): January
Publisher : Universitas Muhammadiyah Yogyakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18196/mmjkk.v24i1.18655

Abstract

Anemia is a health problem worldwide, especially in pregnancy, as it can cause depression. Antenatal depression can cause impaired fetal growth and development, bleeding and abortion, prematurity, low birth weight babies, and postpartum depression. This research aims to determine the difference in levels of depression between anemia and non-anemia in the third trimester of pregnancy. It is an observational study with a cross-sectional design. The samples were 75 last-trimester pregnant women who did antenatal care in Diponegoro National and Amino Gondohutomo Hospital, and also Halmahera and Ngesrep Health Center in Semarang and willling to be respondents selected using a purposive sampling method. Data collection used a validated Edinburgh Postnatal Depression Scale (EPDS) questionnaire with a Content Validity Index (CVI) of 1.00 and a reliability of 0.706. Mann Whitney and Kruskal Wallis were utilized to analyze data. There were 38 respondents with anemia and 37 respondents without anemia. The 12 respondents (31.6%) with anemia had a risk of depression, and 13 respondents (35.1%) without anemia had a risk of depression. There was no significant difference in the level of depression in the third trimester of pregnancy with and without anemia (P0,05). 
Case Report: Pregnancy with Fetal Hydrathorax Putra, Aditya Arya; Wicaksono, Rahmad Rizal Budi; Pramono, M. Besari Adi; Rini, Arsita Eka
Diponegoro International Medical Journal Vol 2, No 2 (2021): December
Publisher : Faculty of Medicine, Diponegoro University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14710/dimj.v2i2.11060

Abstract

Background: Cases of fetal hydrothorax (FHT) are rare, with an occurrence probability of 1 in every 10,000-15,000 pregnancies. The condition may remain undiagnosed, and the fetus may be aborted, or death may occur soon after birth in outlying hospitals before transfer to a tertiary care center. The incidence rate of FHT is higher in males than females (2:1). One of the most effective methods of diagnosing fetal hydrothorax is sonography. Three forms of currently available treatments are: thoracentesis, thoracoamniotic shunting (TAS), and thoracomaternal cutaneous drainage. Fetal outcomes could be improved by performing the Extrauterine Intrapartum Treatment (EXIT) procedure.Case Presentation: We present two cases of first pregnancy primary FHT. In the first case, a 24-year-old woman was diagnosed with asymptomatic FHT in the 28th week of gestation without any prior history. In the second case, a 22-year-old woman with poor medical history was diagnosed in the 35th week of pregnancy and was experienced difficulty of breathing. Both pregnancies were delivered by cesarean section based on obstetric indications. Thoracentesis was performed on both neonates, and pathological examination of the pleural fluid was conducted. However, they died shortly after birth.Conclusion: The EXIT procedure is still a challenging method. A fetus with FHT is at significant risk of pulmonary hypoplasia and respiratory distress following delivery. Early diagnosis and intervention of FHT are vital to ensure a good prognosis. Approaching multidisciplinary groups, providing supportive diagnostic facilities and financial support is essential in improving fetal outcomes and preventing FHT in subsequent pregnancies.
Low sEng Level in Preeclampsia with MFTHFR Gene Polymorphism Suggesting a Protective Factor Pramono, M. Besari Adi; Faradz, Sultana MH; Suhartono, Suhartono; Susanto, Hardhono; Rachmawati, Banundari; Pramono, Noor
Journal of Biomedicine and Translational Research Vol 11, No 3 (2025): December 2025
Publisher : Faculty of Medicine, Universitas Diponegoro

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14710/jbtr.v11i3.29375

Abstract

Background: Preeclampsia is one of the most serious complications of pregnancy and the leading cause of maternal and fetal mortality. Various studies have shown that Glutathione Peroxidase (GPx) deficiency and increased Soluble endoglin (sEng) level are consistently associated with the incidence of preeclampsia. Several studies also show the role of MTHFR A1298C and C677T gene polymorphisms in preeclampsia.Objective: This study investigated association between blood GPx, sEng levels, MTHFR A1298C and C677T gene polymorphisms in Preeclampsia.Methods: This analytic observational case-control study was conducted on 70 cases of preeclampsia and 70 controls. Blood GPx and sEng levels were measured using Enzyme Linked Immunosorbent Assay (ELISA). MTHFR A1298C and C677T gene polymorphism was genotyped using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP). The data obtained were analyzed using the Mann-Whitney U test, chi-square test, and independent T-test.Results: There were no significant differences in GPx levels or MTHFR A1298C/C677T genotype distribution between groups. sEng levels were significantly higher in the preeclampsia group than controls (p=0.001). ROC analysis identified a cut-off of 7.75 ng/mL. Among preeclampsia patients, those with the MTHFR 1298AC/CC genotypes had lower sEng levels than wildtype (p=0.027), suggesting a potential protective effect. No association was found for C677T.Conclusion: We found no significant difference in GPx level, MTHFR A1298C and C677T gene polymorphism between preeclampsia and control group. Soluble endoglin (sEng) level in the preeclampsia group (mean: 11.0±5.22) were significantly different (p=0.001) compared to the control group (mean: 8.1±5.31). Increased level of sEng is associated with incidence of preeclampsia. A key finding in this study is the significantly lower sEng levels observed in preeclampsia patients carrying the MTHFR 1298AC and 1298CC alleles compared to the control group (p=0.027). This indicates a protective factor where in preeclampsia with MTHFR gene alleles 1298AC and 1298CC sEng levels are lower compared to wildtype.
Comparison of Effectiveness Cost Therapy and Increasing Level of Haemoglobin, Ferritin in Pregnant Women with Anemia Whom Are Given Iron Tablet Everyday and Every Two Days Irawan, Agung Pramartha; Pramono, M. Besari Adi; Wijayanti, Asih
Medica Hospitalia : Journal of Clinical Medicine Vol. 13 No. 1 (2026): Med Hosp
Publisher : RSUP Dr. Kariadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36408/mhjcm.v13i1.1338

Abstract

BACKGROUND: Anemia is common in pregnancy, with a prevalence of 48.9% in Indonesia (Riskesdas 2018). It increases the risk of impaired fetal growth, stunting, and intellectual disorders. Iron supplementation, as recommended by Permenkes No. 88/2014, is a key preventive strategy. Evidence such as Moretti et al. (2015), suggests that alternate-day supplementation improves absorption due to reduced hepcidin activity. AIM: To evaluate the effectiveness of administering iron tablets every two days in terms of treatment cost, increases in hemoglobin (Hb) and ferritin levels, and incidence of gastrointestinal adverse effects. METHODS: This was a true experimental study using a randomized pre–post test control group design. The control group received iron tablets daily for two months, while the intervention group received iron tablets every two days. The study was conducted at the Obstetrics and Gynecology Polyclinic of Kariadi Central General Hospital and Halmahera Primary Health Care over eight months (December 2023 – July 2024). Each group included 23 subjects. Body weight, hemoglobin, and ferritin were measured at baseline and after two months. Adverse effects and neonatal outcomes were also documented. RESULTS: Baseline characteristics were normally distributed. The intervention group showed a significant increase in hemoglobin and ferritin levels, higher neonatal birth weight, and lower treatment cost and adverse effects compared to the control group (p < 0.05). Post-treatment differences between groups were 0.5 g/dL for hemoglobin and 17.2 ng/mL for ferritin. CONCLUSION: Administering iron tablets every two days is effective in improving hemoglobin and ferritin levels in pregnant women with anemia and is also cost-effective with fewer adverse effects.
Co-Authors Arsita Eka Rini Asih Wijayanti, Asih Banundari Rachmawati Hardhono Susanto Irawan, Agung Pramartha Natalia Dewi Wardani Noor Pramono Primada, Lyla Fitrania Putra, Aditya Arya Sultana MH Faradz Wicaksono, Rahmad Rizal Budi